Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
Top Cited Papers
Open Access
- 14 June 2012
- Vol. 344 (jun14 1), e3675
- https://doi.org/10.1136/bmj.e3675
Abstract
OBJECTIVE: To analyse clinical outcomes with new oral anticoagulants for prophylaxis against venous thromboembolism after total hip or knee replacement.DESIGN: Systematic review, meta-analysis, and indirect treatment comparisons.DATA SOURCES: Medline and CENTRAL (up to April 2011), clinical trials registers, conference proceedings, and websites of regulatory agencies.STUDY SELECTION: Randomised controlled trials of rivaroxaban, dabigatran, or apixaban compared with enoxaparin for prophylaxis against venous thromboembolism after total hip or knee replacement. Two investigators independently extracted data. Relative risks of symptomatic venous thromboembolism, clinically relevant bleeding, deaths, and a net clinical endpoint (composite of symptomatic venous thromboembolism, major bleeding, and death) were estimated using a random effect meta-analysis. RevMan and ITC software were used for direct and indirect comparisons, respectively.RESULTS: 16 trials in 38,747 patients were included. Compared with enoxaparin, the risk of symptomatic venous thromboembolism was lower with rivaroxaban (relative risk 0.48, 95% confidence interval 0.31 to 0.75) and similar with dabigatran (0.71, 0.23 to 2.12) and apixaban (0.82, 0.41 to 1.64). Compared with enoxaparin, the relative risk of clinically relevant bleeding was higher with rivaroxaban (1.25, 1.05 to 1.49), similar with dabigatran (1.12, 0.94 to 1.35), and lower with apixaban (0.82, 0.69 to 0.98). The treatments did not differ on the net clinical endpoint in direct or indirect comparisons.CONCLUSIONS: A higher efficacy of new anticoagulants was generally associated with a higher bleeding tendency. The new anticoagulants did not differ significantly for efficacy and safety.This publication has 44 references indexed in Scilit:
- Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacementInternational Orthopaedics, 2011
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip ReplacementThe New England Journal of Medicine, 2010
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementThe New England Journal of Medicine, 2009
- Triggers, targets and treatments for thrombosisNature, 2008
- Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgeryJournal of Thrombosis and Haemostasis, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Incidence of symptomatic venous thromboembolism after different elective or urgent surgical proceduresThrombosis and Haemostasis, 2003
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986